Key Points
- Director Dino Rossi sold 18,950 shares on Feb. 19 at an average price of $261.41 for proceeds of about $4.95 million, reducing his stake by 19.41% to 78,691 shares; the transaction was disclosed on an SEC Form 4.
- Krystal Biotech beat quarterly estimates, reporting EPS of $1.70 vs. $1.62 expected and revenue of $107.1M vs. $105.3M, and several analysts raised price targets—consensus target about $318.75 with a "Moderate Buy" rating.
- The stock is trading higher (around $274.59, up ~4.9%), with a market cap near $8.03B and a P/E of ~40; its one‑year range is $122.80 to $298.30 and the 50/200-day moving averages are $266.13/$211.66.
Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) Director Dino Rossi sold 18,950 shares of the business's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $261.41, for a total transaction of $4,953,719.50. Following the completion of the sale, the director directly owned 78,691 shares of the company's stock, valued at $20,570,614.31. This represents a 19.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Krystal Biotech Trading Up 4.9%
Krystal Biotech stock opened at $274.59 on Tuesday. The company has a market capitalization of $8.03 billion, a P/E ratio of 40.09 and a beta of 0.49. The firm's fifty day simple moving average is $266.13 and its 200-day simple moving average is $211.66. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $298.30.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Tuesday, February 17th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.08. The firm had revenue of $107.11 million during the quarter, compared to analysts' expectations of $105.30 million. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. On average, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.
Hedge Funds Weigh In On Krystal Biotech
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. UMB Bank n.a. increased its holdings in shares of Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company's stock worth $36,000 after purchasing an additional 37 shares during the period. Optimize Financial Inc grew its position in Krystal Biotech by 1.4% during the fourth quarter. Optimize Financial Inc now owns 2,855 shares of the company's stock worth $704,000 after buying an additional 40 shares in the last quarter. Perigon Wealth Management LLC increased its stake in Krystal Biotech by 0.5% during the fourth quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company's stock valued at $2,211,000 after acquiring an additional 41 shares during the period. Regal Investment Advisors LLC raised its holdings in Krystal Biotech by 1.0% in the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company's stock valued at $1,075,000 after acquiring an additional 44 shares in the last quarter. Finally, Crossmark Global Holdings Inc. lifted its position in shares of Krystal Biotech by 2.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,124 shares of the company's stock worth $524,000 after acquiring an additional 55 shares during the period. Institutional investors own 86.29% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the company. Jefferies Financial Group increased their price objective on Krystal Biotech from $310.00 to $371.00 and gave the company a "buy" rating in a report on Tuesday, February 17th. Citigroup increased their price target on Krystal Biotech from $336.00 to $371.00 and gave the company a "buy" rating in a report on Wednesday, February 18th. Chardan Capital lifted their price target on shares of Krystal Biotech from $220.00 to $323.00 and gave the company a "buy" rating in a research report on Wednesday, February 18th. Bank of America upped their price objective on shares of Krystal Biotech from $288.00 to $318.00 and gave the stock a "buy" rating in a report on Thursday, January 22nd. Finally, Weiss Ratings upgraded shares of Krystal Biotech from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, February 18th. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $318.75.
View Our Latest Research Report on KRYS
About Krystal Biotech
(
Get Free Report)
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
